EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes following in vitro and in vivo models of stroke

Quentin Marlier, Alexia Boreux, Arnaud Rives, Dario Mosca, Helene Michaux, Louisa Schmitz, Pierre Attali, Stéphane Silvente, Philippe Lefebvre, Brigitte Malgrange, Nicolas Caron

Frontiers in Stroke · 19.06.2026 · 5

DOI: 10.3389/fstro.2026.1802085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Stroke, online erschienen am 19.06.2026. Verfasst von Quentin Marlier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dendrogenix, Liège, Belgium. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Service Public de Wallonie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

New therapeutic strategies to mitigate the devastating consequences of stroke are urgently needed, as restoration of blood flow is currently the only and limited available treatment.

Methods

In our study, we employed a comprehensive combination of in vitro and in vivo stroke models to investigate the therapeutic potential of the DX243. Specifically, we used glutamate and oxygen-glucose deprivation/reoxygenation (OGD) treatment models to mimic ischemic conditions in vitro . To transpose these data in vivo , we used the middle cerebral artery occlusion (MCAO) model to induce an ischemic stroke in male C57BL/6J mice.

Results

Our results demonstrated that DX243 significantly increased ATP production following glutamate treatment and neuronal viability following OGD.Forty-eight hours after 1 h of MCAO, mice that received one subcutaneous injection of DX243 presented a reduced infarct volume and preserved motor coordination on the rotarod, while effects on open field locomotion were not statistically significant.

Conclusion

These results highlight the promising neurorestorative properties of this new molecule and suggest its potential as a therapeutic agent for stroke patients. Further investigations in preclinical and clinical settings are warranted to elucidate its full therapeutic potential.

Schlagwörter

Stichwörter der Autor:innen

MCAOischemiapharmacologicalstroketreatment

Autor:innen und Institutionen

  • Dendrogenix, Liège, Belgium.
  • Laboratory of Developmental Neurobiology, GIGA Institute, University of Liège, Liège, Belgium.

Förderung

  • Service Public de Wallonie

Zitieren

APA

Marlier, Q., Boreux, A., Rives, A., Mosca, D., Michaux, H., Schmitz, L., Attali, P., Silvente, S., Lefebvre, P., Malgrange, B., & Caron, N. (2026). Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes following in vitro and in vivo models of stroke. Frontiers in Stroke, 5. https://doi.org/10.3389/fstro.2026.1802085

Vancouver

Marlier Q, Boreux A, Rives A, Mosca D, Michaux H, Schmitz L, et al. Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes following in vitro and in vivo models of stroke. Frontiers in Stroke. 2026;5. doi:10.3389/fstro.2026.1802085

BibTeX
@article{Marlier2026,
  author = {Marlier, Quentin and Boreux, Alexia and Rives, Arnaud and Mosca, Dario and Michaux, Helene and Schmitz, Louisa and Attali, Pierre and Silvente, Stéphane and Lefebvre, Philippe and Malgrange, Brigitte and Caron, Nicolas},
  title = {Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes following in vitro and in vivo models of stroke},
  journal = {Frontiers in Stroke},
  year = {2026},
  volume = {5},
  doi = {10.3389/fstro.2026.1802085}
}
Kostenlos starten →